Compare LPL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPL | GPCR |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.8B |
| IPO Year | 2004 | 2023 |
| Metric | LPL | GPCR |
|---|---|---|
| Price | $3.32 | $38.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $103.17 |
| AVG Volume (30 Days) | ★ 2.2M | 755.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.76 | $20.04 |
| 52 Week High | $5.83 | $94.90 |
| Indicator | LPL | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 27.86 |
| Support Level | $2.76 | $36.11 |
| Resistance Level | $3.43 | $41.50 |
| Average True Range (ATR) | 0.10 | 2.45 |
| MACD | -0.01 | -1.11 |
| Stochastic Oscillator | 5.26 | 2.07 |
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.